ANT 3273 / Antabio - LARVOL DELTA

Effect of novel LasB inhibitor ANT3273 on activation of IL-1β in macrophage and mouse Pseudomonas aeruginosa infection models (ERS 2022) - "THP-1 macrophages were infected with strain PA01, or its ΔlasB mutant, and levels of LasB activity and IL-1β activation in cell supernatants, in the presence of increasing concentrations of ANT3273 (+/- caspase inhibitor VX-765, 5 μM), were determined by following (a) hydrolysis of fluorogenic IL-1β pro-peptide substrate and (b) IL-1 signal induction in a cell reporter assay. Conclusions. These results indicate the potential of ANT3273 to suppress inflammation and bacterial burden in PA infection."

Preclinical • Immunology • Infectious Disease • Inflammation • Respiratory Diseases • ELANE • IL1B

Prevalence of LasB elastase variants from Pseudomonas aeruginosa respiratory isolates and their inhibition by novel LasB inhibitor ANT3273 (ERS 2022) - "These results indicate that lasB is highly conserved among PA isolates and that all common LasB variants are inhibitable by ANT3273. Our findings support LasB as a valid target for ANT3273-based therapy."

Bronchiectasis • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases • ELANE

"Meet @antabio at #ECCMID2021 ✅#Poster3147 Interaction of the new β-lactamase inhibitor ANT3310 with clinically relevant β-lactamases ✅#Poster4372 Structural & biochemical characterisation of ANT3273, a novel antivirulence compound, with Pseudomonas aeruginosa LasB elastase" (@antabio)

Clinical • ELANE